Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Operating Expenses (2017 - 2025)

Dianthus Therapeutics has reported Operating Expenses over the past 8 years, most recently at $40.7 million for Q3 2025.

  • Quarterly results put Operating Expenses at $40.7 million for Q3 2025, up 26.85% from a year ago — trailing twelve months through Sep 2025 was $143.4 million (up 53.12% YoY), and the annual figure for FY2024 was $108.1 million, up 111.96%.
  • Operating Expenses for Q3 2025 was $40.7 million at Dianthus Therapeutics, up from $35.1 million in the prior quarter.
  • Over the last five years, Operating Expenses for DNTH hit a ceiling of $40.7 million in Q3 2025 and a floor of -$23.0 million in Q4 2022.
  • Median Operating Expenses over the past 4 years was $18.8 million (2023), compared with a mean of $19.8 million.
  • Biggest five-year swings in Operating Expenses: plummeted 65.77% in 2023 and later skyrocketed 226.33% in 2024.
  • Dianthus Therapeutics' Operating Expenses stood at -$23.0 million in 2022, then soared by 181.5% to $18.8 million in 2023, then soared by 76.98% to $33.2 million in 2024, then grew by 22.39% to $40.7 million in 2025.
  • The last three reported values for Operating Expenses were $40.7 million (Q3 2025), $35.1 million (Q2 2025), and $34.3 million (Q1 2025) per Business Quant data.